Home > Journals > Minerva Cardioangiologica > Past Issues > Articles online first > Minerva Cardioangiologica 2017 Oct 25

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

Minerva Cardioangiologica 2017 Oct 25

DOI: 10.23736/S0026-4725.17.04534-0

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Freeway paclitaxel-releasing balloons to treat recurrent stenosis of arteriovenous fistula in hemodialysis patients

Nicola TROISI , Piefrancesco FROSINI, Eugenio ROMANO, Azzurra GUIDOTTI, Emiliano CHISCI, Stefano MICHELAGNOLI

Department of Surgery, Vascular and Endovascular Surgery Unit, San Giovanni di Dio Hospital, Florence, Italy


PDF  


BACKGROUND: To evaluate early and mid-term outcomes of Freeway paclitaxel-releasing balloons (Eurocor GmbH, Bonn, GE) in hemodialysis patients with recurrent stenosis of arteriovenous fistula.
METHODS: Between July 2013 and December 2016 27 hemodialysis patients with recurrent stenosis of arteriovenous fistula underwent endovascular treatment with a Freeway balloon. About inclusion criteria, all patients were previously treated at the target lesion with a standard balloon angioplasty (BA). The intervals in months between standard BA and procedure with DCB (time BA-DCB) and between procedure with DCB and new restenosis (time DCBrestenosis) were evaluated and compared with T-test. 2-year estimated outcomes in terms of survival, primary patency, primary assisted patency, secondary patency, and freedom from target lesion restenosis (TLR) were assessed with Kaplan-Meier curves.
RESULTS: Technical success was obtained in 96.3% of the cases. During the follow-up (mean duration 13.6 months, range 1-33) 13 patients (48.1%) had a new restenosis. Mean time BA-DCB was 4.8 months, and the mean time DCB-restenosis was 7.6 months with a statistically significant difference at T-test (P<0.001). Estimated 2-year rates of primary patency, primary assisted patency, secondary patency, and freedom from TLR were 31.8%, 76.4%, 90.5%, and 30.2%, respectively.
CONCLUSIONS: In our experience Freeway paclitaxel-releasing balloons were effective in the treatment of recurrent stenosis in hemodialysis patients previously treated with standard BA. At follow-up about half of patients had no new target lesion restenosis and the time to a new restenosis was much longer compared to recurrence of stenosis after standard BA.


KEY WORDS: Drug-coated balloon - Arteriovenous fistula - Hemodialysis - Recurrent stenosis

top of page

Publication History

Article first published online: October 25, 2017
Manuscript accepted: October 17, 2017
Manuscript received: October 8, 2017

Cite this article as

Troisi N, Frosini P, Romano E, Guidotti A, Chisci E, Michelagnoli S. Freeway paclitaxel-releasing balloons to treat recurrent stenosis of arteriovenous fistula in hemodialysis patients. Minerva Cardioangiol 2017 Oct 25. DOI: 10.23736/S0026-4725.17.04534-0

Corresponding author e-mail

troisimd@gmail.com